Biotechnology IP Checklist: Eligibility and Scope, Sequence Listings and Deposits, Written Description Evidence, Resource Provenance, and Collaboration Terms

By Casey Scott McKay · 2024-05-25

This checklist builds a biotechnology IP position in the order that makes the later steps possible, and it begins where the losses actually happen. Phase one puts a gate in front of publication, because in this field the abstract nobody reviewed destroys the foreign family and nothing later recovers it. Phase two screens eligibility before scope, since the answer determines what kind of claim is worth pursuing and in which jurisdiction. The middle phases plan the variant data that now substitutes for functional genus language, reconcile sequence listings against the specification, diarise deposit obligations individually, and build the provenance register that governs every biological input from arrival through commercialisation. The closing phases cover collaboration and university terms, freedom to operate across the manufacturing workflow, the exclusivity stack, trade secret controls for process know-how, and the diligence pack investors now expect.

IP and Technology > Patent Counseling Transactions | Checklist | Published 25 May 2024 - Updated 17 May 2025 | Casey Scott McKay - marksy.us

Summary. This checklist builds a biotechnology IP position in the order that makes the later steps possible, and it begins where the losses actually happen. Phase one puts a gate in front of publication, because in this field the abstract nobody reviewed destroys the foreign family and nothing later recovers it. Phase two screens eligibility before scope, since the answer determines what kind of claim is worth pursuing and in which jurisdiction. The middle phases plan the variant data that now substitutes for functional genus language, reconcile sequence listings against the specification, diarise deposit obligations individually, and build the provenance register that governs every biological input from arrival through commercialisation. The closing phases cover collaboration and university terms, freedom to operate across the manufacturing workflow, the exclusivity stack, trade secret controls for process know-how, and the diligence pack investors now expect.

Keywords: biotechnology checklist · publication gate · eligibility screening · sequence defined claims · variant data planning · written description evidence · sequence listing reconciliation · Budapest deposit diary · derivation records · material provenance register · access and benefit sharing · donor consent scope · material transfer reach-through · research safe harbour transition · tool licence audit · regulatory exclusivity mapping · term extension selection · manufacturing trade secrets · university licence diligence · investor diligence pack

How to use this checklist

| Field | Detail | |---|---| | Who runs it | Patent counsel with the project scientist, regulatory affairs, and whoever holds the material records | | When | At project start; before every filing; before every submission; annually across the estate | | Time required | Three weeks for a first pass on one programme; ongoing thereafter | | Gates | Publication reviewed before submission; eligibility screened before drafting; provenance recorded on arrival | | Output | A publication gate, a claim strategy by jurisdiction, a provenance register, and a deposit diary | | Companion documents | Protecting a Biotechnology Invention and Claiming Life |

The matter. A company spun out of a university two years ago is developing a therapeutic antibody against a target its founder characterised in an academic laboratory. The founding technology is in-licensed under a university agreement nobody at the company has read in full. Twenty-six antibodies have been made, all from one immunisation campaign, and the draft claims define the class by binding affinity and neutralising activity. A conference abstract describing the target correlation was published fourteen months ago. The cell line came from a collaborator in another country under a one-page material transfer agreement. A diagnostic application based on the same correlation is also being drafted. Nobody has checked the deposit requirements, the sequence listing format, or whether the founder's continuing academic laboratory is generating inventions the company does not own.

Phase 1. Put a gate in front of publication

[ ] Route every external document through one named reviewer. Manuscripts, abstracts, posters, preprints, grant reports, conference submissions, investigator brochures. Why. The abstract nobody reviewed is the most common cause of lost foreign rights in this field. Trap. A review process covering journal articles only.
[ ] Make a provisional filing the default, not the discussion. Why. People comply with a default; they route around a debate. Trap. A policy requiring a meeting before every filing decision.
[ ] Commit to a short review window and meet it. Two weeks, honoured. Why. Researchers comply with a commitment that is kept and evade an indefinite hold. Trap. A technology transfer queue with no service level.
[ ] Treat a preprint as a publication on the day posted. Why. For absolute-novelty jurisdictions that date is decisive; 35 U.S.C. § 102(b) protects only the domestic position and only for twelve months. Trap. Treating peer review acceptance as the publication date.
[ ] Check whether the funder publishes grant applications or progress reports. Why. Researchers do not consider them disclosures. Trap. A review list drawn from the publications database.
[ ] [Gate] No external disclosure without a recorded filing decision. Why. It is the only control that works. Trap. Exceptions granted for "preliminary" material, which is where the enabling disclosure usually sits.

Phase 2. Screen eligibility before scope

[ ] Classify the invention: naturally occurring, engineered, method of treatment, or diagnostic correlation. Why. The category determines what is worth drafting. Trap. A single application covering all four with one claim strategy.
[ ] Accept that isolated naturally occurring material is not eligible. Why. Association for Molecular Pathology v. Myriad Genetics; cDNA and engineered constructs remain eligible. Trap. A composition claim to a purified natural product with no structural difference.
[ ] Treat diagnostic correlations as the hardest category. Why. Mayo Collaborative Services v. Prometheus Laboratories through the Alice Corp. v. CLS Bank International framework, applied in Ariosa Diagnostics v. Sequenom and Athena Diagnostics v. Mayo Collaborative Services. Trap. Assuming that scientific significance answers the eligibility question. It does not.
[ ] Build the unconventionality record for any diagnostic claim. What was actually available to detect this, at this sensitivity, at that date. Why. It is the only route through the second step. Trap. A specification describing the detection steps as routine because that was the honest scientific framing.
[ ] Design the claim set jurisdiction by jurisdiction. Why. Europe permits claims to isolated biological material produced by a technical process and excludes methods of treatment practised on the body; the two claim sets are structurally different. Trap. Drafting domestically and translating.
[ ] Reconsider which jurisdiction is primary for a diagnostic. Why. Frequently it is not the United States, and the budget should follow. Trap. A domestic-first filing plan applied reflexively.

Phase 3. Plan the data before drafting the claim

[ ] Count the variants and map where they came from. Why. Twenty-six antibodies from one immunisation campaign support a claim to those antibodies, not to a class. Trap. Treating variant count as sufficient without considering diversity of origin.
[ ] Accept that functional genus claims will not hold. Why. Amgen Inc. v. Sanofi holds that a roadmap for trial-and-error screening is not enablement. Trap. Drafting the broad claim anyway "to see what happens", which anchors the file badly.
[ ] Plan additional variant generation deliberately to support the intended breadth, from different origins where possible. Why. Scope now comes from sequences described. Trap. Variant generation planned to answer the scientific question only.
[ ] Identify the structural feature that correlates with function and describe it. Why. Ariad Pharmaceuticals v. Eli Lilly allows possession to be shown by common structural features, which is the alternative to counting species. Trap. A specification that says what the molecules do and never says why.
[ ] Use enumerated substitutions rather than functional variability. Why. AbbVie Deutschland v. Janssen Biotech and Juno Therapeutics v. Kite Pharma show what happens to functionally defined classes. Trap. "Or a functional equivalent thereof" inserted late in drafting.
[ ] Support any percentage identity band with data across it. Why. Identity limits are structural but inherit the enablement problem when wide and unsupported. Trap. Ninety per cent identity claimed on the basis of one variant.
[ ] Claim manufacturing and formulation separately. Why. For a biologic these are frequently the most enforceable rights, being structural, detectable in a regulatory filing, and hard to design around. Trap. A patent estate consisting entirely of composition claims.
[ ] [Gate] Do not file until the data supports the claim you intend to defend. Why. A continuation inherits the disclosure; it does not add examples. Trap. Filing to a financing timetable.

Phase 4. Get the formalities right

[ ] Reconcile the sequence listing against the specification text before filing. Why. The requirements at 37 C.F.R. § 1.831 and following make the listing part of the disclosure, and a mismatch surfaces on amendment when it is too late. Trap. Listing preparation treated as a formatting task delegated outside the drafting team.
[ ] Confirm the listing meets the current standard. Why. Listings prepared under earlier standards are not simply convertible and require annotation older records may lack. Trap. Reusing a family's original listing in a continuation.
[ ] Decide whether a deposit is required. Why. Needed where the material cannot be reproducibly described and is not otherwise available; 37 C.F.R. § 1.801 and following govern, under the Budapest Treaty. Trap. Depositing reflexively, which discloses the material to anyone entitled to a sample once the patent issues.
[ ] Diarise each deposit obligation separately. Timing, recognised depositary, removal of restrictions, viability confirmation, replacement. Why. Each has independently invalidated patents. Trap. A single diary entry labelled "deposit".
[ ] Keep derivation-quality records throughout. Witnessed conception and reduction to practice, dated grant applications, conference disclosures, internal messages about what was and was not working. Why. Derivation proceedings under 35 U.S.C. § 135 and priority disputes turn on these. Trap. Electronic notebooks with no witnessing and no retention policy.

Phase 5. Build the provenance register

[ ] Open a record for every biological input on the day it arrives. Source organism and location, supplier or collection, date, permit or agreement, use restrictions, publication restrictions, benefit-sharing obligations. Why. Reconstruction later is close to impossible and investors now ask. Trap. A freezer inventory that records what is held and not where it came from.
[ ] Apply the Convention on Biological Diversity framework to foreign-sourced material. Why. A company obtaining material from a party state is subject to that state's access legislation regardless of its own country's status. Trap. Treating non-party status as an exemption.
[ ] Anticipate disclosure-of-origin requirements in offices that impose them. Why. Consequences range from procedural objection to revocation. Trap. A single global specification with no origin statement.
[ ] Treat digital sequence information as within scope. Why. The direction of travel is that obligations attach to sequences derived from sampled organisms even without physical transfer. Trap. Assuming a database download is unencumbered.
[ ] Route every material transfer agreement through counsel before signature. Why. Reach-through provisions claiming rights in resulting inventions encumber programmes permanently. Trap. Agreements signed by the receiving scientist as a routine courtesy.
[ ] Check donor consent scope for human-derived material. Sequencing, data sharing, commercialisation, derivative lines, and whether it names the current holder. Why. It determines what the asset actually is. Trap. Relying on the collaborator's assurance.
[ ] Record community engagement outcomes for population studies. Why. Agreements reached there constrain downstream use and bind successors. Trap. Treating engagement as a research ethics step with no commercial consequence.

Phase 6. Read the university and collaboration paper

[ ] Read the university licence in full, not the summary. Why. Diligence milestones, minimum royalties, field limitations, sublicensing consent, reversion rights, and reserved research rights each change the value of the asset. Trap. A data room summary that omits two of them.
[ ] Diarise every diligence milestone. Why. A milestone missed by a company whose programme moved elsewhere is a termination risk nobody is monitoring. Trap. Discovering the milestone in a notice of breach.
[ ] Check the reserved research rights. Why. Some reservations extend to research funded by commercial sponsors, which can place a competitor inside the fence. Trap. Reading the grant clause and not the reservation.
[ ] Verify the institution's own chain of title. Inventor assignments, visiting researchers, material from other institutions. Why. Warranties are usually limited to knowledge. Trap. Assuming an institution's internal policy operated as an assignment.
[ ] Map federal funding obligations. Invention reporting, election of title, government licence, manufacturing preference. Why. Some failures are curable and some are not. Trap. Assuming compliance because the institution says so.
[ ] Paper the founder's continuing academic laboratory. Why. Inventions made there in the same field raise ownership questions turning on which hat was worn and whose resources were used. Trap. Leaving it until the second-generation invention matters.
[ ] In consortium arrangements, schedule background before work starts. Why. Unscheduled background becomes contested background exactly when results have value. Trap. A background definition by formula rather than by list.
[ ] Allocate foreground by field with cross-licences, not by contributor. Why. Ownership determined by who happened to invent produces an estate nobody can license. Trap. Joint ownership chosen because it appears fair; 35 U.S.C. § 262 lets every co-owner license and 35 U.S.C. § 116 makes a contributor to one claim an inventor of the whole patent.

Phase 7. Freedom to operate across the workflow

[ ] Map the whole workflow, not the product. Vectors, promoters, markers, cell lines, media, resins, analytical methods, editing systems. Why. A clean composition position says nothing about the tools. Trap. A clearance search run on the therapeutic sequence alone.
[ ] Separate development from commercial manufacture in the analysis. Why. 35 U.S.C. § 271(e)(1), read broadly in Merck KGaA v. Integra Lifesciences I, covers much preclinical and clinical work. Trap. Concluding a tool patent is irrelevant without noting when the harbour ends.
[ ] Diarise the safe harbour transition date. Why. Licences that were unnecessary must be in place before commercial manufacture, and the negotiation position is far worse afterwards. Trap. Discovering it during technology transfer to a manufacturer.
[ ] Audit the licence chain on every in-licensed tool. Sublicensing rights, field, territory, and the licensor's own right to grant. Why. Tools arriving through academic collaborations are the weak point. Trap. Relying on a licence granted by a party that held only a non-exclusive licence itself.
[ ] Assess eligibility as part of the risk analysis. Why. A blocking diagnostic claim may not survive Mayo, and treating every issued claim as enforceable overstates risk in this field. Trap. A clearance opinion that never questions validity.
[ ] Aggregate reach-through and royalty obligations across every agreement. Why. The total is frequently larger than anyone has computed and appears in no patent search. Trap. Tracking royalties per agreement and never summing them.

Phase 8. Map the exclusivity stack

[ ] List every exclusivity, not just the patents. Why. Regulatory exclusivity under 42 U.S.C. § 262 runs independently, cannot be invalidated, and survives a lost patent case. Trap. A board slide showing patent expiry as the cliff.
[ ] Add orphan, paediatric, and new entity exclusivities where available. Why. They are obtained through regulatory practice and can exceed the value of a marginal patent family. Trap. Regulatory and patent functions each assuming the other is tracking them.
[ ] Select the 35 U.S.C. § 156 extension patent deliberately. Why. One patent per approved product; in biologics the manufacturing claim is frequently the better choice. Trap. Defaulting to the composition patent.
[ ] Protect term adjustment during prosecution. Why. Biotechnology prosecution is slow and applicant delay reduces adjustment at the most valuable end of the life cycle. Trap. Routine extensions of time taken for convenience.
[ ] Plan the biosimilar interface early. Why. The information exchange under 42 U.S.C. § 262 structures the first litigation wave, and Sandoz v. Amgen held the disclosure step is not federally enforceable by injunction. Trap. Assuming control over timing the statute does not provide.

Phase 9. Protect the process

[ ] Identify what is genuinely secret. Cell line history, clone selection, media and feed strategy, bioreactor parameters, purification schedule, analytical methods. Why. Most of the rest is disclosed or inferable. Trap. Uniform controls applied to everything and therefore effective nowhere.
[ ] Test the programme against 18 U.S.C. § 1839. Why. Reasonable measures are an element of any claim under the Defend Trade Secrets Act. Trap. A policy with no access segregation behind it.
[ ] Include the 18 U.S.C. § 1833 whistleblower notice. Why. Omission forfeits exemplary damages and fees against that person. Trap. Notice in the handbook rather than the agreement.
[ ] Compartmentalise across the manufacturing route. Why. A departure carrying one compartment is survivable. Trap. A single master batch record with universal access.
[ ] Paper the contract manufacturer properly. Ownership of improvements, prohibition on use for others, destruction obligations, subcontractor coverage, audit rights. Why. Process transfer hands over the entire know-how estate. Trap. A quality agreement with no IP terms.
[ ] Run exit forensics for anyone with process access. Why. Manufacturing parameters travel in a spreadsheet. Trap. Exit procedures triggered by seniority.

Phase 10. Assemble the diligence pack before it is requested

[ ] Chain of title on the founding technology, with assignment records and the licence itself.
[ ] Government funding compliance evidence, not assertions.
[ ] The material provenance register, complete and current.
[ ] Donor consent scope documentation for human-derived material.
[ ] Aggregate royalty and reach-through computation across all agreements.
[ ] Publication history mapped against filing dates, jurisdiction by jurisdiction.
[ ] Deposit compliance confirmed at the depositary, not from the file.
[ ] Freedom to operate on the manufacturing workflow, with the safe harbour transition date.

Why. Every one of these is now a standard request, and assembling them under time pressure produces incomplete answers that read as concealment. Trap. Preparing the patent schedule and nothing else.

Phase 11. Working the example matter

[ ] Assess the fourteen-month-old conference abstract first. Why. It is outside the twelve-month domestic grace period in 35 U.S.C. § 102(b) and outside every absolute-novelty jurisdiction. What matters is precisely what it enabled: if it disclosed the target correlation but not the antibodies, the antibody claims survive and the diagnostic claims may not. Obtain the abstract text, not the recollection of it. Trap. Assuming an abstract was too brief to matter, which is how this exact loss occurs.
[ ] Read the university licence in full this week. Why. A licence nobody at the company has read is the highest-probability defect in the estate, and diligence milestones, field limits, and reserved research rights all change the company's position materially. Trap. Asking the founder what it says.
[ ] Stop the functional antibody claim and plan more variants. Why. Twenty-six antibodies from a single immunisation campaign, claimed by binding affinity and neutralising activity, is close to the fact pattern in Amgen Inc. v. Sanofi. The response is a second campaign from a different origin, structural characterisation of the binding site, and claims defined by sequence with enumerated substitutions. Trap. Filing broad now and narrowing later, which spends the disclosure without buying the scope.
[ ] Reconsider the diagnostic application entirely. Why. A correlation detected by conventional means faces Mayo Collaborative Services v. Prometheus Laboratories and Ariosa Diagnostics v. Sequenom, and the abstract may have destroyed the foreign position that would otherwise have been the better market. Consider whether the commercial value sits in a therapeutic method claim instead. Trap. Filing the diagnostic application because it was drafted.
[ ] Trace the cell line to its source. Why. A one-page material transfer agreement from a collaborator in another country raises access legislation compliance, reach-through, and possibly donor consent if the line is human-derived. This is a diligence item that will be found. Trap. Continuing to use the line while the question is open, which compounds the problem.
[ ] Paper the founder's academic laboratory now. Why. A founder running a laboratory in the same field will generate inventions whose ownership depends on hats, resources, and institutional policy. It is a governance conversation today and a dispute in three years. Trap. Deferring because the relationship is good, which is exactly why now is the time.
[ ] Check deposit requirements against the claim set. Why. If any claim depends on material not reproducibly describable, a deposit is required, and the timing rules do not forgive lateness. Trap. Assuming a sequence listing substitutes for a deposit.
[ ] [Gate] Freeze filings until the abstract scope, the licence terms, and the variant plan are settled. Why. Each changes what should be filed and where. Trap. A filing programme driven by a financing round rather than by the record.

Phase 12. Annual estate review

[ ] Sample five materials from the freezer inventory and request their provenance records. Why. The failure rate in that sample is the honest measure of the register. Trap. Auditing the register against itself.
[ ] Re-map claims to the current programme. Why. Biotechnology programmes pivot, and estates drift toward protecting the abandoned indication. Trap. Renewal decisions made on cost rather than relevance.
[ ] Review the exclusivity stack and the cliff dates. Why. The commercial response to a cliff needs years of lead time and frequently involves manufacturing rather than patents. Trap. A single expiry date reported to the board.
[ ] Check every open deposit, confidentiality, and diligence deadline. Why. These are the deadlines that invalidate rights or terminate licences silently. Trap. A diary maintained by an individual rather than by the system.
[ ] Audit publication compliance. How many external documents went out, how many were reviewed, what was filed first. Why. It is the measure that predicts foreign portfolio quality. Trap. Measuring filings without measuring disclosures.
[ ] Re-run the tool freedom to operate against the current manufacturing process. Why. Processes change during scale-up, and a clearance done on the research process does not cover the commercial one. Trap. A clearance opinion treated as permanent.

Phase 13. Regulatory affairs coordination

[ ] Review regulatory submissions for statements inconsistent with the patent position. Why. Assertions about mechanism, comparability, and what is conventional in the field are producible in litigation. Trap. Two functions writing about the same product to different standards.
[ ] Treat trial registration and results posting as publication deadlines. Why. Where the invention lies in a dosing regimen or patient selection criterion, the posting timetable is a novelty deadline. Trap. A publication gate that covers scientific literature only.
[ ] Add investigator brochures and consent documents to the disclosure list. Why. They describe the intervention in detail to people under no confidentiality obligation. Trap. Assuming clinical documents are confidential because they are not published.
[ ] Feed regulatory characterisation data into continuation practice. Why. The analytical package assembled for a submission frequently contains exactly the structural characterisation a written description argument needs. Trap. Generating it after the family has closed.
[ ] Assign the 35 U.S.C. § 156 extension application to a named person on both sides. Why. The deadline after approval is short and unforgiving. Trap. Each function assuming the other is tracking it.
[ ] Hold a quarterly joint review. Upcoming submissions, publications, filings, and deadlines on both sides. Why. One hour catches most of what falls between the functions. Trap. Coordination attempted through document circulation.

Phase 14. Computational discovery

[ ] Document who defined the objective, constraints, and selection criteria. Why. Inventorship remains human, and conception will be located in those decisions. Trap. Reconstructing the account after a challenge.
[ ] Preserve the evidence of what the field predicted. Why. Where computational generation and screening is routine, obvious-to-try arguments become more available and contemporaneous evidence is the answer. Trap. Discarding the model outputs that failed.
[ ] Track training data provenance into the outputs. Why. A model trained on structures obtained under material transfer agreements or access obligations carries those obligations forward. Trap. Treating an internal model as unencumbered because no material was transferred.
[ ] Decide whether the model or the molecule is the asset before drafting. Why. Describing the model supports enablement and discloses it; describing it thinly preserves secrecy and invites a sufficiency objection. Trap. Splitting the difference, which achieves neither.

Phase 15. Documents this checklist should produce

[ ] A publication gate log. Every external document, reviewer, date, filing decision. Why. It is the evidence that the process exists and the measure of whether it works. Trap. A policy with no log behind it.
[ ] A claim strategy by jurisdiction. What is claimed where, and why the sets differ. Why. The domestic and European claim sets are structurally different and both need a rationale. Trap. One claim set translated.
[ ] A variant and data plan tied to the intended claim scope, with generation scheduled before filing. Why. Scope now comes from sequences described. Trap. A plan written after the first rejection.
[ ] A material provenance register, opened on arrival, complete for every input. Why. It is a diligence item, a validity question in some offices, and unreconstructable later. Trap. A freezer inventory presented as a provenance register.
[ ] A deadline diary covering deposits, confidentiality reassertions, diligence milestones, and the safe harbour transition. Why. These are the deadlines that silently destroy rights. Trap. A diary held by one person.
[ ] A standing diligence pack, maintained rather than assembled. Why. Assembly under time pressure produces answers that read as concealment. Trap. Building it when the term sheet arrives.

Phase 16. Self-replicating and environmental subject matter

[ ] Identify whether the invention reproduces. Engineered micro-organisms, cell lines, phage, yeast strains, seed, and any construct that propagates. Why. Exhaustion analysis changes: Bowman v. Monsanto holds that making new copies is not permitted by exhaustion. Trap. Applying ordinary product exhaustion reasoning to a living article.
[ ] Build the contractual layer regardless of the patent position. Technology use agreements, bailment structures, propagation restrictions. Why. These carry the commercial relationship and are enforceable as contracts whatever the patent analysis says. Trap. Relying on patent rights alone against a customer who can simply grow more.
[ ] Address inadvertent replication in the enforcement policy. Why. Where an organism spreads without any act by the possessor, the reasoning in Bowman does not obviously apply and no decision has settled it. Trap. An enforcement programme that treats presence as proof of infringement.
[ ] Map the regulatory position for environmental release separately. Why. Release approvals, biosafety review, and transboundary movement rules operate independently of the IP analysis and can prohibit what the patent permits. Trap. An IP-led launch plan for a released organism.
[ ] Comply with sequence screening obligations for synthesis orders. Why. Providers screen against sequences of concern, and funders increasingly require use of screening providers, making it a contractual and grant condition. Trap. Ordering through an unscreened provider to save time.
[ ] Trace every component of a multi-part construct. Why. A single restrictively licensed part encumbers the finished organism, and reconstruction after assembly is difficult. Trap. Assuming an open framework applies to the whole construct because most parts came from one.

Phase 17. Enforcement readiness

[ ] Audit the company's own publications for inconsistent use of every claim term. Why. Terms used loosely in papers and precisely in claims are construed against the patentee. Trap. Discovering the inconsistency in a claim construction brief.
[ ] Define and contest the person of ordinary skill early. Why. Whether routine screening was available to that person decides enablement, obviousness, and much of written description. Trap. Accepting the opponent's definition and litigating downstream of it.
[ ] Assemble the filing-date art record before asserting. Reviews, grant applications, contemporaneous statements about difficulty. Why. It is the strongest evidence on enablement and non-obviousness and becomes hard to find as the field moves. Trap. Building it during expert discovery.
[ ] Screen for inequitable conduct exposure. Inventors' own publications, prior art known to them, inconsistent foreign statements, omitted data. Why. Biotechnology files are unusually rich in material nobody asked the inventors about. Trap. Asserting first and auditing afterwards.
[ ] Model the forum choice around section 112 grounds. Why. Enablement and written description are unavailable in inter partes review, which makes the nine-month post-grant window and district court the relevant venues. Trap. Assuming the challenger's options are the same as in other technologies.
[ ] Plan damages and injunction evidence as technical evidence. Why. Apportionment, lost profits between non-competitors, and independent regulatory exclusivity all rest on facts the technical team holds, and public interest arguments carry real weight on injunctive relief in this field. Trap. Handing damages to economists with no technical input.

Phase 18. Proportion and sequencing

[ ] Do the publication gate first, and do not let anything displace it. Why. It prevents more loss than everything else on this list combined, and it costs one reviewer and a form. Trap. Starting with the filing programme because it is the visible work.
[ ] Open the provenance register second. Why. It is cheap while material is arriving and impossible to reconstruct afterwards. Trap. Deferring it until a diligence request forces it.
[ ] Concentrate the remaining effort on three things. The lead asset's composition and manufacturing estate; the provenance of every material touching it; the variant data that supports the claim you intend to defend. Why. Even investment across a whole pipeline produces a large portfolio of thin filings and no defensible position on the asset that matters. Trap. A filing target expressed as a number of applications.
[ ] Run everything else on a lighter process. Standard disclosure form, default provisional, annual prune. Why. Proportionate effort is what makes the process survive contact with a research organisation. Trap. A single heavyweight process applied to every disclosure, which is abandoned within a year.

Phase 19. Two questions to ask at the first meeting

[ ] "Where did the material come from, and who else has rights in it?" Why. The answer reshapes the filing plan more often than the science does, and it is the question nobody asks because it sounds administrative. Trap. Asking the scientific lead rather than whoever signed the transfer agreement.
[ ] "What has been published, and when?" Why. It determines which jurisdictions remain available and therefore where the budget should go. Trap. Accepting a list of journal articles as a complete answer, when the abstracts, posters, preprints, and grant reports are where the disclosure usually sits.

[ ] And one question to ask the board. "If every patent in this estate were invalidated tomorrow, what would still stop a competitor?" Why. In most biologics programmes the honest answer is manufacturing know-how and regulatory exclusivity, and that answer should be driving the investment. Trap. A protection strategy built around the asset that is easiest to describe rather than the one that lasts longest.

[ ] A final note on tone with scientists. Every control in this checklist is a constraint on people whose careers depend on disclosure and whose instinct is to share material freely. Explain the reason rather than issuing the rule, keep the review windows short enough to be credible, and accept that a process people follow imperfectly is worth more than one they route around entirely.

Outcome. A publication gate that catches abstracts as well as papers; a claim strategy designed jurisdiction by jurisdiction with variant data planned to support it; sequence listings reconciled and deposit obligations individually diarised; a provenance register opened on arrival for every material; collaboration and university terms read in full and diarised; and a diligence pack that exists before anyone asks for it.

The five things people get wrong

One. Reviewing papers and not abstracts. Conference abstracts are submitted months ahead, published on acceptance, and almost never reviewed. They are the single largest source of lost foreign rights in biotechnology, and the fix is a one-line change to the review list.

Two. Drafting the functional genus claim anyway. After Amgen Inc. v. Sanofi there is no drafting route to a broad class defined by what the molecules do. Filing it regardless anchors the prosecution badly, produces a file history full of concessions, and delays the moment the company starts generating the variants that would have given it real scope.

Three. Treating provenance as an administrative record. Where material came from, under what agreement, with what obligations, is now a diligence item priced by investors and a validity question in offices with disclosure-of-origin requirements. It cannot be reconstructed once the postdoc who collected it has left.

Four. Assuming the research safe harbour lasts. 35 U.S.C. § 271(e)(1) is a regulatory safe harbour with a regulatory boundary. The date it stops applying is knowable years in advance, and programmes routinely discover it during technology transfer, when every licence negotiation is conducted from the weakest possible position.

Five. Reporting patent expiry as the exclusivity cliff. In biologics the last protection standing is usually manufacturing know-how and manufacturing patents, with regulatory exclusivity running independently of both. A strategy built around the composition claim optimises the wrong asset.

Key Authorities at a Glance

| Authority | Proposition | |---|---| | 35 U.S.C. § 101 | Patentable subject matter | | 35 U.S.C. § 102 | Novelty; grace period | | 35 U.S.C. § 103 | Obviousness | | 35 U.S.C. § 112 | Enablement; written description | | 35 U.S.C. § 116 | Joint inventors | | 35 U.S.C. § 135 | Derivation | | 35 U.S.C. § 154 | Term and adjustment | | 35 U.S.C. § 156 | Term extension | | 35 U.S.C. § 262 | Joint owners | | 35 U.S.C. § 271 | Infringement; safe harbour | | 42 U.S.C. § 262 | Biologics and biosimilars | | 18 U.S.C. § 1833 | Whistleblower notice | | 18 U.S.C. § 1836 | DTSA civil action | | 18 U.S.C. § 1839 | Trade secret definition | | 37 C.F.R. § 1.801 | Deposits | | 37 C.F.R. § 1.831 | Sequence listings | | 37 C.F.R. § 1.132 | Declarations | | Diamond v. Chakrabarty | Human-made organism | | Mayo Collaborative Services v. Prometheus Laboratories | Natural law claims | | Association for Molecular Pathology v. Myriad Genetics | Isolated DNA | | Alice Corp. v. CLS Bank International | Eligibility framework | | Amgen Inc. v. Sanofi | Full-scope enablement | | Merck KGaA v. Integra Lifesciences I | Safe harbour scope | | Sandoz v. Amgen | Biosimilar procedure | | Bowman v. Monsanto | Self-replicating articles | | Ariad Pharmaceuticals v. Eli Lilly | Written description | | Centocor Ortho Biotech v. Abbott Laboratories | Antibody genus | | AbbVie Deutschland v. Janssen Biotech | Functional genus | | Ariosa Diagnostics v. Sequenom | Diagnostic eligibility | | Athena Diagnostics v. Mayo Collaborative Services | Diagnostic claims | | Juno Therapeutics v. Kite Pharma | Constructs | | In re Wands | Undue experimentation | | Budapest Treaty | Deposit system | | Nagoya Protocol | Benefit sharing | | Sequence listing standard | Listing format | | Disclosure of origin | Source disclosure |